Earendil Labs Raises $787 Million in Latest Funding Round
Earendil Labs, a biotechnology company based in Wilmington, Delaware, has successfully raised $787 million in its latest funding round, announced on March 19, 2026. The company specializes in developing technology platforms that leverage deep learning and high-throughput biology to revolutionize the discovery of protein therapeutics.
Investors
The funding round saw participation from several prominent investors, including Dimension Capital, DST Global, INCE Capital, Luminous Ventures, Miracle Capital, Sanofi, and the Biotech Development Fund, a collaboration between Hillhouse and Pfizer. While the round's lead investor was not disclosed, the involvement of these major players highlights significant confidence in Earendil Labs' innovative approach.
Company Leadership
Earendil Labs was founded by Jian Peng, who serves as the CEO, and Zhenping Zhu, who holds the position of President and Co-CEO. The leadership team is focused on harnessing cutting-edge technology to push the boundaries of biologics development.
Use of Funds
While specific plans for the newly acquired funds were not detailed in the announcement, the substantial investment is expected to support the company’s ongoing efforts to enhance its technology platforms. This could include further development of their deep learning algorithms and expansion of their high-throughput biology capabilities to accelerate the discovery of next-generation protein therapeutics.
Conclusion
This significant funding round positions Earendil Labs to make substantial advancements in the biotechnology sector, particularly in the realm of protein therapeutics. As the company continues to innovate, it remains at the forefront of integrating AI and biology to drive new medical discoveries.